Literature DB >> 21301483

Exploiting human herpesvirus immune evasion for therapeutic gain: potential and pitfalls.

Daniëlle Horst1, Maaike E Ressing, Emmanuel J H J Wiertz.   

Abstract

Herpesviruses stand out for their capacity to establish lifelong infections of immunocompetent hosts, generally without causing overt symptoms. Herpesviruses are equipped with sophisticated immune evasion strategies, allowing these viruses to persist for life despite the presence of a strong antiviral immune response. Although viral evasion tactics appear to target virtually any stage of the innate and adaptive host immune response, detailed knowledge is now available on the molecular mechanisms underlying herpesvirus obstruction of MHC class I-restricted antigen presentation to T cells. This opens the way for clinical application. Here, we review and discuss recent efforts to exploit human herpesvirus MHC class I evasion strategies for the rational design of novel strategies for vaccine development, cancer treatment, transplant protection and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21301483     DOI: 10.1038/icb.2010.129

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  10 in total

Review 1.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

2.  Self-boosting vaccines and their implications for herd immunity.

Authors:  Nimalan Arinaminpathy; Jennie S Lavine; Bryan T Grenfell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-19       Impact factor: 11.205

3.  Immune regulation and evasion of Mammalian host cell immunity during viral infection.

Authors:  B M Pratheek; Soham Saha; Prasanta K Maiti; Soma Chattopadhyay; Subhasis Chattopadhyay
Journal:  Indian J Virol       Date:  2013-03-15

4.  CD8(+) T cells from mice transnuclear for a TCR that recognizes a single H-2K(b)-restricted MHV68 epitope derived from gB-ORF8 help control infection.

Authors:  Sharvan Sehrawat; Oktay Kirak; Paul-Albert Koenig; Marisa K Isaacson; Sofia Marques; Gunes Bozkurt; J Pedro Simas; Rudolph Jaenisch; Hidde L Ploegh
Journal:  Cell Rep       Date:  2012-04-26       Impact factor: 9.423

Review 5.  Hiding lipid presentation: viral interference with CD1d-restricted invariant natural killer T (iNKT) cell activation.

Authors:  Daniëlle Horst; Ruben J Geerdink; Anna M Gram; Arie J Stoppelenburg; Maaike E Ressing
Journal:  Viruses       Date:  2012-10-23       Impact factor: 5.048

6.  Deletion of parasite immune modulatory sequences combined with immune activating signals enhances vaccine mediated protection against filarial nematodes.

Authors:  Simon A Babayan; Honglin Luo; Nick Gray; David W Taylor; Judith E Allen
Journal:  PLoS Negl Trop Dis       Date:  2012-12-27

7.  TAP mediates import of Mycobacterium tuberculosis-derived peptides into phagosomes and facilitates loading onto HLA-I.

Authors:  Melanie J Harriff; Sven Burgdorf; Christian Kurts; Emmanuel J H J Wiertz; Deborah A Lewinsohn; David M Lewinsohn
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

Review 8.  Opportunistic intruders: how viruses orchestrate ER functions to infect cells.

Authors:  Madhu Sudhan Ravindran; Parikshit Bagchi; Corey Nathaniel Cunningham; Billy Tsai
Journal:  Nat Rev Microbiol       Date:  2016-06-06       Impact factor: 60.633

9.  Viral miRNAs Alter Host Cell miRNA Profiles and Modulate Innate Immune Responses.

Authors:  Afsar R Naqvi; Jennifer Shango; Alexandra Seal; Deepak Shukla; Salvador Nares
Journal:  Front Immunol       Date:  2018-03-06       Impact factor: 7.561

10.  Mechanism of activation of the BNLF2a immune evasion gene of Epstein-Barr virus by Zta.

Authors:  Rajaei Almohammed; Kay Osborn; Sharada Ramasubramanyan; Ijiel Barak Naranjo Perez-Fernandez; Anja Godfrey; Erika J Mancini; Alison J Sinclair
Journal:  J Gen Virol       Date:  2018-03-26       Impact factor: 3.891

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.